Clarity Pharmaceuticals Ltd: Supply agreement for Ac-225 with TerraPower Isotopes
Clarity Pharmaceuticals Ltd: Clarity Receives $10 million R&D Tax Incentive
Clarity Pharmaceuticals Ltd: Clarity Confirms No Supply Disruptions for Clinical Trials
Clarity Pharmaceuticals Ltd: Clarity strengthens Cu-64 network with new supply agreement
Clarity Pharmaceuticals Ltd: Change of Director's Interest Notice - Rob Thomas
Clarity Pharmaceuticals Ltd: Clarity to Present at 3 World Leading Conferences
Clarity Pharmaceuticals Ltd: Change of Director's Interest Notice - Thomas
Clarity Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Clarity Pharmaceuticals Ltd: Complete response with Cu-67 SAR-bisPSMA
Clarity Pharmaceuticals Ltd: Clarity enters into Clinical Supply Agreement
Clarity Pharmaceuticals Ltd: Trading Halt
Clarity Pharmaceuticals Ltd: First participant treated in the last dose escalation cohort
Clarity Pharmaceuticals Ltd: Change of Director's Interest Notice
Clarity Pharmaceuticals Ltd: Theranostic prostate cancer trial advances to multi-dose
Clarity Pharmaceuticals Ltd: Additional COBRA trial data results
Clarity Pharmaceuticals Ltd: Correction to 2023 Annual Report
Clarity Pharmaceuticals Ltd: Initial COBRA results
Clarity Pharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Clarity Pharmaceuticals Ltd: Final Director's Interest Notice
Clarity Pharmaceuticals Ltd: First patient dosed in Phase III prostate cancer trial
No Data